Best Peptides for Muscle Growth & Recovery: What Works, What's Legal, What's Hype

Key takeaways

• No injectable peptide has a randomized trial showing it builds muscle in healthy adults. That is the finding, not a caveat. Everything sold as a muscle peptide is either a growth hormone secretagogue with hormone data and little else, or a healing or growth-factor peptide with animal data only.
• The compound with real muscle evidence is testosterone, which is not a peptide: 600 mg a week for 10 weeks added about 6 kg of fat-free mass with training in the classic trial. It is a controlled substance prescribed for diagnosed deficiency, and it belongs in this guide as the benchmark the peptides are measured against.
• Among peptides a US clinician can legally prescribe in October 2026, tesamorelin and sermorelin raise growth hormone and IGF-1; tesamorelin has large trials for visceral fat, and sermorelin small trials showing hormone changes with modest strength signals and no body-composition change.
• MK-677 (ibutamoren) is an oral non-peptide secretagogue with the best body-composition trial of the group: about 1 kg of fat-free mass over a year in older adults, no strength gain, higher fasting glucose, and a heart-failure signal in a later trial. FDA put it in Category 2 in 2023 and its committee voted against it in October 2024.
• BPC-157 and TB-500 are animal-tested healing peptides that cannot yet be compounded; IGF-1 LR3 has no human data and no legal source; follistatin and 'myostatin inhibitor' peptides are hype. Anyone with an active cancer, diabetes or a pregnancy should not use growth hormone secretagogues at all.

How we ranked

We ranked by four things, in this order: the quality of human evidence for muscle or body composition (graded A to D as in our editorial policy), whether a licensed US pharmacy can legally dispense it in October 2026, the safety record, and cost. Popularity did not count. If a compound is everywhere on social media and nowhere in the clinical literature, it ranks low here, and if the honest number one is not a peptide, we say so.

"Muscle growth" means a measured increase in fat-free mass, muscle cross-sectional area or strength in a controlled human study. Hormone levels are not muscle. A rise in IGF-1 is a mechanism, and mechanisms are where most peptide marketing stops.

The ranking at a glance

Prices are October 2026 figures from our cost guide. Legal status follows our legal tracker.

1. Testosterone: not a peptide, but the benchmark

Any honest guide to muscle compounds has to start here, because testosterone is the only drug on the list with unambiguous evidence, and because many "peptide clinics" are prescribing it alongside the peptides.

In the trial that settled the question, 43 healthy men were randomized to placebo or 600 mg of testosterone enanthate weekly for 10 weeks, with or without supervised lifting. Men on testosterone plus training gained 6.1 kg of fat-free mass, grew their triceps and quadriceps cross-sections by about 500 and 1,170 square millimeters, and added 22 kg to their bench press and 38 kg to their squat. Men on testosterone who did not train still gained more muscle size and strength than men on placebo (Bhasin 1996).

Two things keep testosterone from being a casual recommendation. The trial dose is several times what replacement therapy uses, and the clinical use of testosterone is the treatment of diagnosed hypogonadism (two low morning levels plus symptoms), not muscle growth in men with normal levels. It is a Schedule III controlled substance; prescribing it for physique is outside its labeling and, in most states, outside what a medical board will tolerate. In 790 symptomatic men aged 65 and older with low testosterone, a year of replacement gel improved sexual function and mood modestly and did not improve walking distance or vitality, and the investigators judged the trials too small to settle the risks (Snyder 2016).

Where it belongs in a muscle conversation: if a clinician has documented low testosterone, replacement is the intervention with evidence, and it costs less than most peptides ($99 to $289 a month all-in through telehealth). If testosterone is normal, no peptide on this page will substitute for it, and a clinic that suggests otherwise is selling.

2. Tesamorelin: the GHRH analog with large trials (for fat, not muscle)

Tesamorelin is a stabilized version of full-length GHRH, FDA-approved as Egrifta for excess abdominal fat in people with HIV. It is the only wellness-marketed secretagogue with phase 3 data. In the pooled analysis of two 26-week placebo-controlled trials, 806 patients on antiretroviral therapy were randomized to 2 mg daily or placebo: visceral fat fell by a treatment effect of 15.4%, IGF-1 rose by about 108 ng/mL, triglycerides improved, the reduction held through 52 weeks in those who continued, and glucose did not change in a clinically meaningful way (Falutz 2010).

What those trials did not measure is muscle. Tesamorelin preserves subcutaneous fat and shifts body composition, but no trial has shown it adds strength or muscle mass in anyone, and its wellness use in people without HIV is extrapolation from a different population. It can be legally prescribed only as the brand, Egrifta, at about $2,400 to $2,800 a month; FDA regulates tesamorelin as a biological product, so the cheaper 'compounded tesamorelin' some clinics sell is not made under a compounding exemption FDA recognizes. Read the tesamorelin profile for the trial detail and the dose gap between 2 mg daily and clinic protocols.

3. Sermorelin: prescribable, physiological, and not a muscle drug

Sermorelin is the first 29 amino acids of GHRH, formerly approved for growth hormone deficiency in children and now compounded on prescription. In 10 healthy men around age 68, 1 mg injected twice daily for 14 days restored 24-hour GH output and IGF-1 to the levels of men in their twenties; the 0.5 mg dose did not (Corpas 1992). In the one trial that measured muscle, 11 men aged 64 to 76 self-injected 2 mg nightly for six weeks: overnight GH rose, two of six strength measures (upright row and shoulder press) and an abdominal endurance test improved, but DEXA-measured muscle and fat did not change and IGF-1 did not rise (Vittone 1997).

That is the whole muscle record for sermorelin: a hint of strength in a six-week study with no body-composition change, at a dose four to ten times what telehealth programs prescribe (usually 200 to 500 mcg nightly). It earns its place in this ranking because it is legal, feedback-preserving, inexpensive relative to the alternatives ($150 to $400 a month) and the right tool for a documented low IGF-1. It does not earn the word "muscle." The sermorelin profile covers the doses, monitoring and side effects.

4. MK-677 (ibutamoren): the oral secretagogue with a two-year trial and a legal problem

MK-677 is not a peptide. It is an oral small molecule, developed by Merck, that activates the ghrelin receptor and raises GH and IGF-1 with a daily pill. It is sold with peptides because it does what the injectable secretagogues promise, with a better evidence base and the same legal status.

The key trial randomized 65 healthy adults aged 60 to 81 to 25 mg of MK-677 or placebo daily for two years. GH and IGF-1 rose to young-adult levels. At one year, fat-free mass had increased by 1.1 kg in the MK-677 group and decreased by 0.5 kg on placebo; body weight rose 2.7 kg versus 0.8 kg; limb fat increased more on the drug; visceral fat and total fat did not differ. Fasting glucose rose by about 5 mg/dL, insulin sensitivity fell, cortisol rose modestly, LDL cholesterol fell slightly, and the common side effects were increased appetite that faded over months, transient leg swelling and muscle pain. The added fat-free mass produced no change in strength or function, and the two-year results confirmed the one-year ones (Nass 2008).

A later trial in 123 older adults recovering from hip fracture, 25 mg daily for 24 weeks, raised IGF-1 by 51 ng/mL and improved gait speed but no other functional measure, and was terminated early because of a congestive heart failure signal in a small number of patients; the authors concluded the drug had an unfavorable safety profile in that population (Adunsky 2011). A 563-patient Alzheimer's trial of the same 25 mg dose raised IGF-1 by 73% over 12 months and changed nothing clinically (Sevigny 2008). Merck did not pursue approval.

The 2018 review of secretagogues in humans summarizes the class fairly: generally well tolerated in short studies, consistent concern about blood glucose from reduced insulin sensitivity, and no data on long-term cancer incidence or mortality (Sigalos 2018).

Legally, MK-677 travels with the peptides. FDA added ibutamoren mesylate to Category 2 of its compounding list on September 29, 2023, citing significant safety risks, alongside ipamorelin, CJC-1295 and BPC-157 (FDA categories update 2023). On October 29, 2024, FDA's Pharmacy Compounding Advisory Committee reviewed it (for growth hormone deficiency, bone, muscle loss, obesity and Alzheimer's disease) and voted against adding it to the permitted list, along with ipamorelin, kisspeptin-10 and L-theanine (APC 2024). No US pharmacy may compound it, and the capsules sold online are unregulated research chemicals.

5. CJC-1295 + ipamorelin: the most popular stack with the least data

The combination of a long-acting GHRH analog with a selective ghrelin-receptor agonist is the most-prescribed "muscle stack" in wellness clinics and the one with the thinnest file. CJC-1295 with DAC raised GH 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for 9 to 11 days after a single injection in healthy adults; ipamorelin has a pharmacokinetic study in 40 men and a failed trial in bowel recovery after surgery. Neither has a body-composition trial, nobody has tested the combination, and the nightly microgram doses clinics sell have never been studied. FDA placed both in Category 2 in September 2023, and its committee voted against ipamorelin (0 yes, 12 no, 1 abstention) in October 2024 and against CJC-1295 (0 yes, 13 no; 1 yes, 12 no for the acetate) in December 2024. The CJC-1295/ipamorelin profile has the full account. For muscle purposes the summary is short: grade C on hormones, grade D on muscle, and no legal supply.

6. BPC-157 and TB-500: healing claims, not muscle growth

BPC-157 (a fragment of a gastric protein) and TB-500 (a fragment of thymosin beta-4) are sold for recovery, and recovery gets folded into "muscle growth" in the marketing. The evidence is entirely in animals. A 2019 review of BPC-157 for soft-tissue healing found consistently positive results across rodent injury models and stated plainly that efficacy "is yet to be confirmed in humans" (Gwyer 2019). For TB-500, FDA's own reviewers told the July 2026 advisory committee they could not identify a single human clinical study, and that the product's sequence and molecular weight vary by vendor (Hyman Phelps 2026).

Neither has ever been tested for muscle mass or strength in a human, which puts them at grade D for this guide regardless of how they do on tendon healing in rats. Legally they are in transition: FDA removed both from Category 2 in April 2026 and its committee voted 8 to 6 in July 2026 to recommend adding them to the permitted list, but FDA has not completed rulemaking, so as of October 2026 no pharmacy may compound them and every vial on the market is a research chemical. Our BPC-157, TB-500 and Wolverine stack pages cover the animal data and the 2026 votes.

7. IGF-1 LR3: no human data, no legal source

IGF-1 is the hormone that carries most of growth hormone's effect on muscle, and "Long R3 IGF-1" is a modified version engineered for cell-culture work, with a substitution that keeps it from binding the proteins that normally buffer IGF-1 in blood. It is sold to bodybuilders as the direct route to the anabolic signal.

There is no human study of IGF-1 LR3. None. Our PubMed search in October 2026 found no clinical trial of any kind, and the only human-relevant literature is in anti-doping chemistry. What exists is the approved human IGF-1, mecasermin (Increlex), which tells you what the molecule does when a regulated version is given to people: it is indicated only for children with severe primary IGF-1 deficiency, it is contraindicated in anyone with a malignancy or a history of one, and its warnings include hypoglycemia, intracranial hypertension and lymphoid tissue hypertrophy (Increlex label). A version designed to escape the body's binding proteins, injected by adults with no monitoring, takes each of those risks and removes the brake. There is no FDA category to cite because nobody has nominated it for compounding; it has simply never been legal to sell for human use.

8. Follistatin and 'myostatin inhibitor' peptides: hype

Myostatin limits muscle growth, and blocking it is a legitimate research target. The problem is what is being sold. "Follistatin-344" vials are a research protein with no human study; the human follistatin data come from a gene-therapy experiment in a handful of patients with a muscle disease, delivered by viral vector into the thigh, which is not what is in the vial. The only myostatin-pathway trial with muscle outcomes used a monoclonal antibody, LY2495655, in 201 people aged 75 or older who had fallen: monthly injections added 0.43 kg of lean mass versus placebo over 24 weeks and modestly improved some performance tests, with injection-site reactions in 30% (Becker 2015). That is an antibody, in frail elderly people, producing less than half a kilogram. Peptides marketed as myostatin inhibitors to healthy lifters have not been shown to inhibit myostatin in a human, let alone build muscle.

What we excluded and why

• Growth hormone itself. Not a peptide in the marketing sense and not legal for this use: distributing GH for anything other than an FDA-recognized disease is a federal crime (see the legal tracker). The evidence is also underwhelming for the purpose. In a meta-analysis of 11 placebo-controlled trials in healthy young adults, GH increased lean mass and decreased fat but did not improve muscle strength or aerobic capacity (Hermansen 2017); in healthy elderly people it shifted about 2 kg of fat to lean mass and caused more edema, joint pain, carpal tunnel syndrome and glucose problems (Liu 2007).
• GHRP-2, GHRP-6 and hexarelin. Older ghrelin-receptor agonists that raise cortisol and prolactin along with GH. FDA listed GHRP-2 and GHRP-6 in Category 3 (nominated without adequate support) in 2023 (FDA categories update 2023); none can be compounded, and none has muscle data.
• Collagen peptides. These are the one "peptide" with randomized body-composition data in otherwise healthy adults: in 53 men with sarcopenia (mean age 72) doing 12 weeks of resistance training, 15 g a day of collagen peptides added 4.2 kg of fat-free mass versus 2.9 kg on placebo and improved quadriceps strength (Zdzieblik 2015). They are hydrolyzed food protein, the effect is the effect of extra protein in people who were not eating enough, and nobody needs a clinic to buy them.
• 'Oral peptides for muscle growth.' Capsules of BPC-157, CJC-1295 or ipamorelin have no absorption data and no reason to work; see the FAQ.
• SARMs. Not peptides, not approved, and outside this guide.

Who should not use growth hormone secretagogues

The secretagogues on this list (tesamorelin, sermorelin, MK-677, CJC-1295, ipamorelin) all raise GH and IGF-1. Whatever the compound, the same people should not use them, or should use them only with a specialist's sign-off:

• Anyone with an active cancer or a recent cancer history. IGF-1 is a growth signal; the approved IGF-1 product is contraindicated in malignancy for that reason (Increlex label), and no secretagogue has been studied for cancer incidence (Sigalos 2018).
• Anyone with diabetes, prediabetes or diabetic retinopathy. Secretagogues reduce insulin sensitivity; MK-677 raised fasting glucose in healthy older adults (Nass 2008), and GH itself raised rates of impaired fasting glucose and new diabetes (Liu 2007).
• Pregnant or breastfeeding women. No data, and growth-factor exposure in pregnancy is not something to test on yourself.
• Anyone with a pituitary disorder, acromegaly or an intracranial mass.
• Anyone with heart failure, given the signal in the MK-677 hip-fracture trial (Adunsky 2011).

Athletes subject to testing should treat every compound on this page as prohibited.

How to get the legal options prescribed

If, after all of that, a GHRH analog still makes sense for you, the path is the same one we describe for sermorelin: a clinician licensed in your state, a baseline IGF-1 and fasting glucose, a named 503A pharmacy on the label, a repeat IGF-1 at 8 to 12 weeks, and a willingness to stop if nothing moves. Tesamorelin is the choice when visceral fat is the problem, filled as brand Egrifta, since no compounding pharmacy may lawfully make it; sermorelin when the goal is a physiological GH nudge at lower cost. If testosterone is low on two morning tests, that is a separate conversation with better evidence and its own monitoring (hematocrit, PSA, fertility).

What to walk away from: any program that bundles a legal prescription with research vials of CJC-1295, ipamorelin, BPC-157 or IGF-1 LR3 as a "muscle stack," any promise of a specific number of pounds of muscle, and any clinic that will not name its pharmacy.

Bottom line

Ranked honestly, the best peptide for muscle growth is a sentence rather than a product: no injectable peptide has been shown to build muscle in a healthy adult. The legal GHRH analogs, tesamorelin and sermorelin, raise growth hormone and IGF-1 under supervision and do modest, measurable things to fat and hormone levels; they are reasonable prescriptions for the right patient and poor substitutes for a barbell. MK-677 has the best secretagogue data and no legal supply. BPC-157, TB-500, IGF-1 LR3 and the myostatin peptides have no human muscle evidence at all. The compound that actually builds muscle is testosterone, which is not a peptide, is prescribed only for deficiency, and is where any serious conversation about pharmacology and muscle has to start and end.

Frequently asked questions

+−What are the top 5 peptides to take for muscle growth?

There is no honest top five, because no injectable peptide has a randomized trial showing muscle growth in healthy adults. Ranked by evidence and legality, the list is short: sermorelin, which a licensed pharmacy can compound, and tesamorelin, which is legal only as the brand Egrifta, are GHRH analogs that raise growth hormone and IGF-1 with modest or unmeasured effects on muscle; everything else marketed for muscle (CJC-1295, ipamorelin, BPC-157, TB-500, IGF-1 LR3, follistatin) either has no human data or cannot be legally compounded, usually both. The compound with real muscle evidence is testosterone, which is not a peptide and is prescribed only for diagnosed deficiency.

+−Is MK-677 a peptide?

No. MK-677 (ibutamoren mesylate) is an oral small molecule that mimics ghrelin at the same receptor ipamorelin acts on. It is often sold alongside peptides because it raises growth hormone and IGF-1 by mouth. It has the best body-composition trial of any secretagogue, a two-year randomized study in 65 older adults, which found about 1 kg more fat-free mass, no gain in strength or function, higher fasting glucose and lower insulin sensitivity. FDA placed it in Category 2 in September 2023 and its advisory committee voted against adding it to the compounding list in October 2024, so no US pharmacy may compound it.

+−How do peptides compare to steroids for muscle growth?

They are not in the same league. In the classic trial, 600 mg of testosterone enanthate a week for 10 weeks added 6.1 kg of fat-free mass and large gains in bench press and squat strength in men who also lifted, and even men who did not train gained muscle size and strength. No peptide has produced anything like that in a trial; the best secretagogue data are about 1 to 2 kg of lean mass with no strength gain. Testosterone is a controlled substance prescribed for diagnosed hypogonadism, not for muscle growth, and those doses are far above replacement.

+−What is the downside of peptides for muscle growth?

Three downsides. First, raising growth hormone and IGF-1 has known costs: fluid retention, joint pain, carpal tunnel symptoms, and higher blood sugar from reduced insulin sensitivity, documented for growth hormone and for MK-677. Second, long-term safety, including cancer incidence, has never been studied for any secretagogue. Third, most muscle peptides sold online are research vials with no pharmacy, no label and no verified content; FDA's 2026 warning letters made clear that a research-use label does not make them legal to sell for human use.

+−Are peptides safe for muscle growth?

The prescribable ones, sermorelin and tesamorelin, were tolerated well in their trials, with injection-site reactions, flushing and headache as the common complaints and glucose as the thing to monitor. The unprescribable ones have either no human safety data at all (BPC-157, TB-500, IGF-1 LR3, follistatin) or short hormone studies only (CJC-1295, ipamorelin). Nobody with an active cancer, uncontrolled diabetes or a pregnancy should use any growth hormone secretagogue.

+−What is the best peptide for muscle growth and fat loss?

For fat, the peptide with large trials is tesamorelin, which cut visceral fat by about 15 percent over 26 weeks in people with HIV-associated abdominal fat, and the drugs with the strongest fat-loss evidence are the GLP-1 agonists, which are peptides but not muscle builders. For muscle, nothing has trial evidence in healthy adults. The honest combination is a GLP-1 for fat loss plus resistance training and adequate protein to keep muscle, with a GHRH analog only if a clinician documents low IGF-1 and measures it again.

+−Are there oral peptides for muscle growth?

Not in a form that is absorbed and works. Peptides of this size are digested like any protein, which is why every secretagogue trial used injections. Capsules sold as oral BPC-157, CJC-1295 or ipamorelin have no published absorption or hormone data. The two oral exceptions are not what the marketing implies: MK-677 is an oral secretagogue with real trial data but it is not a peptide and is not legally compoundable, and collagen peptides are hydrolyzed food protein whose small benefit in trials is the benefit of extra protein.

+−Are peptides for muscle growth legal?

Sermorelin can be legally prescribed and compounded. Tesamorelin can be prescribed only as the brand Egrifta: FDA regulates it as a biological product, which no pharmacy may compound. Testosterone is an approved, controlled drug prescribed for diagnosed deficiency. CJC-1295, ipamorelin and MK-677 were placed in FDA's Category 2 in 2023 and rejected by FDA's advisory committee in 2024, so no pharmacy may compound them. BPC-157 and TB-500 were recommended by the committee in July 2026 but FDA has not completed rulemaking, so as of October 2026 they still cannot be compounded. IGF-1 LR3 and follistatin have no legal source. Possessing any of them is not a crime; selling them for human use without approval is.

+−Does sermorelin build muscle?

Not demonstrably. In the trial that looked, 11 healthy men aged 64 to 76 injected 2 mg of GHRH(1-29) nightly for six weeks: two of six strength measures and one endurance test improved, but body composition by DEXA did not change and IGF-1 did not rise. At the doses clinics prescribe, usually 200 to 500 mcg, there is no body-composition data at all. Sermorelin is a reasonable way to raise growth hormone output under supervision; it is not a muscle-building drug.

Sources

1. StudyBhasin S et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996;335:1-7. (1996)
2. StudySnyder PJ et al. Effects of testosterone treatment in older men. N Engl J Med 2016;374:611-24. (2016)
3. ReviewLiu H et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007;146:104-15. (2007)
4. ReviewHermansen K et al. Impact of GH administration on athletic performance in healthy young adults: a systematic review and meta-analysis of placebo-controlled trials. Growth Horm IGF Res 2017;34:38-44. (2017)
5. StudyFalutz J et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010;95:4291-304. (2010)
6. StudyCorpas E et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and IGF-I levels in old men. J Clin Endocrinol Metab 1992;75:530-5. (1992)
7. StudyVittone J et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism 1997;46:89-96. (1997)
8. StudyNass R et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 2008;149:601-11. (2008)
9. StudyAdunsky A et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr 2011;53:183-9. (2011)
10. StudySevigny JJ et al. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology 2008;71:1702-8. (2008)
11. ReviewSigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev 2018;6:45-53. (2018)
12. ReviewGwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res 2019;377:153-9. (2019)
13. LabelDailyMed. Increlex (mecasermin) injection prescribing information: indication (severe primary IGF-1 deficiency in children 2 years and older), contraindication in malignant neoplasia, warnings for hypoglycemia, intracranial hypertension and lymphoid tissue hypertrophy. Eton Pharmaceuticals, 2026. (2026)
14. StudyBecker C et al. Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol 2015;3:948-57. (2015)
15. StudyZdzieblik D et al. Collagen peptide supplementation in combination with resistance training improves body composition and increases muscle strength in elderly sarcopenic men: a randomised controlled trial. Br J Nutr 2015;114:1237-45. (2015)
16. RegulatoryFDA. Bulk drug substances nominated for use in compounding under section 503A: notice of updates to categories, September 29, 2023 (CJC-1295, ipamorelin acetate, ibutamoren mesylate, BPC-157, thymosin beta-4 fragment and others added to Category 2; GHRP-2 and GHRP-6 listed in Category 3). Copy hosted by the Alliance for Pharmacy Compounding. (2023)
17. NewsAlliance for Pharmacy Compounding. PCAC votes against four nominated bulk drug substances (ibutamoren mesylate, L-theanine, ipamorelin and kisspeptin-10 at the October 29, 2024 meeting). November 2024. (2024)
18. NewsPalmer KL, Snow CD, Bass M. PCAC approves four bulk drug substances for the 503A list (BPC-157, KPV, TB-500, MOTS-c). FDA Law Blog, Hyman Phelps & McNamara, July 24, 2026. (2026)
19. RegulatoryFDA. Bulk drug substances nominated for use in compounding under section 503A: Category 1, 2 and 3 lists and updates (updated May 14, 2026). (2026)